9021 related articles for article (PubMed ID: 16767914)
21. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
[TBL] [Abstract][Full Text] [Related]
22. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
24. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
25. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
26. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
[TBL] [Abstract][Full Text] [Related]
27. Conventional isolated hyperthermic antiblastic perfusion in the treatment of recurrent limb melanoma.
Decian F; Mondini G; Demarchi R; Muzio G; Sementa A; Bocchio MM; Spirito C; Simoni G; Civalleri D
Anticancer Res; 1996; 16(4A):2017-24. PubMed ID: 8712736
[TBL] [Abstract][Full Text] [Related]
28. TNF dose reduction in isolated limb perfusion.
Grünhagen DJ; de Wilt JH; van Geel AN; Graveland WJ; Verhoef C; Eggermont AM
Eur J Surg Oncol; 2005 Nov; 31(9):1011-9. PubMed ID: 16099618
[TBL] [Abstract][Full Text] [Related]
29. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
[TBL] [Abstract][Full Text] [Related]
30. Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
Bonvalot S; de Baere T; Mendiboure J; Paci A; Farace F; Drouard-Troalen L; Bonnet L; Hakime A; Bonniaud G; Raynard B; Israel P; Le Cesne A; Eggermont AM; Laplanche A; Muret J
Ann Surg; 2012 Feb; 255(2):281-6. PubMed ID: 22241290
[TBL] [Abstract][Full Text] [Related]
31. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs.
Lejeune FJ; Eggermont AM
J Clin Oncol; 2007 Apr; 25(11):1449-50; author reply 1450-1. PubMed ID: 17416870
[No Abstract] [Full Text] [Related]
32. Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-alpha.
Laurenzi L; Natoli S; Di Filippo F; Calamaro A; Centulio F; Anzà M; Cavaliere F; Marcelli ME; Garinei R; Arcuri E
J Exp Clin Cancer Res; 2004 Jun; 23(2):225-31. PubMed ID: 15354406
[TBL] [Abstract][Full Text] [Related]
33. [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S
Tumori; 2003; 89(4 Suppl):241-3. PubMed ID: 12903606
[TBL] [Abstract][Full Text] [Related]
34. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
35. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma.
Fletcher WS; Pommier R; Small K
Melanoma Res; 1994 Mar; 4 Suppl 1():17-9. PubMed ID: 8038590
[TBL] [Abstract][Full Text] [Related]
36. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1193-201. PubMed ID: 19224288
[TBL] [Abstract][Full Text] [Related]
37. [Hyperthermic-antiblastic isolation perfusion for advanced melanoma of the limbs. The technic, immediate results and a review of the literature].
Decian F; Balletto N; Camerini G; Depaoli M; D'Aniello R; Ameri A; Brisighella A; Bonalumi U; Bachi V; Civalleri D
Minerva Chir; 1990 Oct; 45(19):1227-37. PubMed ID: 2074944
[TBL] [Abstract][Full Text] [Related]
38. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences.
Cavaliere R; Cavaliere F; Deraco M; Di Filippo F; Santinami M; Schiratti M; Anzà M; Vaglini M
Melanoma Res; 1994 Mar; 4 Suppl 1():5-11. PubMed ID: 8038597
[TBL] [Abstract][Full Text] [Related]
40. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
